Home infusions may help patients stick to treatment
NCT ID NCT07494058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether people with Fabry, Gaucher, or Hunter disease are more likely to continue their IV treatment when it's given at home versus at a hospital. Researchers will review existing data from 222 patients in Mexico. No new treatments are given; the goal is to understand what helps patients stay on track with their infusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could show that home infusions help patients stick to their treatment better than hospital visits.
- What could go wrong
- This is an observational study reviewing existing data, not a controlled trial. Results may not apply to other countries or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Takeda Site
Mexico City, 05348, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early enzyme therapy save kidneys in fabry disease?
- Can continued lucerastat access help fabry patients?
- Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?
- Can a single gene infusion rewrite the story of fabry disease?
- Fabry disease sperm study halted early
- Heart study reveals hidden link between blood vessels and muscle blockage